In Vivo Efficacy CROs for Dog Studies

6 contract research organizations in our directory list both In Vivo Efficacy and Dog among their capabilities, across 3 countries. 6 report GLP capability and 2 report AAALAC accreditation. Confirm species-specific experience with each lab when you get in touch.

6 CROs 6 GLP 2 AAALAC 3 countries

In Vivo Efficacy CROs for Dog Studies

Showing 6 CROs. Order rotates daily so no lab is permanently listed first.

JOINN Laboratories

CN GLP

Large China-based nonclinical CRO offering GLP safety assessment, pharmacology, pharmacokinetics and bioanalysis, with operations in China and the United States.

In Vivo Efficacy Bioanalysis GLP Toxicology Pharmacokinetics Repeat-Dose Toxicity Dog Cynomolgus monkey Non-human Primate Rat

Vivo Bio Tech

IN GLP

Hyderabad-based preclinical CRO offering GLP toxicology, pharmacology and pharmacokinetic studies across rodent and non-rodent species.

In Vivo Efficacy GLP Toxicology Pharmacokinetics Toxicology Dog Mouse Non-human Primate Rabbit

DT&CRO

KR GLP

Korean CRO covering GLP toxicity, PK and efficacy studies through to clinical trials for drugs, devices and other products.

In Vivo Efficacy Bioanalysis GLP Toxicology Medical Device Testing Pharmacokinetics Dog Mouse Rabbit Rat

Aragen Life Sciences

IN GLP

Integrated discovery and development services company in India offering in vivo pharmacology, DMPK, bioanalysis and safety assessment alongside chemistry and biologics services.

In Vivo Efficacy Bioanalysis In Vitro ADME In Vivo PK Toxicology Dog Mouse Rat

CorestemChemon (ChemOn)

KR GLP AAALAC

South Korea's first private non-clinical CRO, providing GLP toxicity, safety pharmacology, pharmacokinetic and efficacy studies for drugs, chemicals and biologics.

In Vivo Efficacy GLP Toxicology Pharmacokinetics Repeat-Dose Toxicity Safety Pharmacology Dog Mouse Rabbit Rat

PharmaLegacy Laboratories

CN GLP AAALAC

Preclinical pharmacology CRO in Shanghai with specialty efficacy models in autoimmunity, inflammation, bone and orthopedics, oncology and metabolic disease, plus supporting PK/PD and exploratory toxicology.

In Vivo Efficacy Bone & Joint Models Inflammation Models Metabolic Disease Models Oncology Models Dog Mouse Non-human Primate Rabbit

Questions to ask when choosing an In Vivo Efficacy in Dog CRO

  • What positive-control data do you have for this model from the past 12 months, and what is the typical effect size and variability?
  • How are animals randomized, and is scoring blind to treatment?
  • How did you choose group size for the primary endpoint?
  • Can PK and biomarker samples be taken from the efficacy animals?
  • How quickly will we see interim data, and in what format?